{"id":34939,"date":"2023-07-21T16:35:17","date_gmt":"2023-07-21T14:35:17","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&p=34939"},"modified":"2024-07-24T13:47:58","modified_gmt":"2024-07-24T11:47:58","slug":"correction-ipsen-provides-update-on-e-u-marketing-authorization-application-for-bylvay-for-cholestatic-pruritus-in-patients-with-alagille-syndrome-2","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/correction-ipsen-provides-update-on-e-u-marketing-authorization-application-for-bylvay-for-cholestatic-pruritus-in-patients-with-alagille-syndrome-2\/","title":{"rendered":"Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay\u00ae for cholestatic pruritus in patients with Alagille syndrome \u00a0"},"content":{"rendered":"\n